Earnings, Revenue Beat Expectations
K12 reported fourth-quarter earnings of $0.05 a share, while analysts had expected a loss of $0.03 a share. Revenue of $170.4 million also beat the $165.39 million consensus estimate. LRN advances 10 percent before the bell on my tradeMONSTER platform.
Licensing Deal Lifts Vical
Vical announced it has licensed its DNA immunization technology and its Vaxfectin, used to produce antibodies, to Bristol-Myers Squibb. VICL climbs 12 percent in early trading
Pall Beats the Street Thanks to U.S. Strength
Pall earned $0.86 a share in its fourth quarter on revenue of $783.7 million. Analysts were looking for just $0.77 and $718.79 million, respectively. Management credited the beat with strong performance in the Americas, while Europe and Asia were flat. PLL rallies 7 percent in the premarket.
More From optionMONSTER